Ebanga™ (ansuvimab-zykl, formerly mAb114) a human monoclonal antibody indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
On 21 December 2020, Ridgeback obtained FDA approval for Ebanga™. Ridgeback is now one of only two companies to obtain FDA approval for a therapeutic against Zaire ebolavirus. Ebanga is currently available to patients, and Ridgeback Biotherapeutics provides and distributes the treatment to patients free of charge in Ebola-stricken countries.
For more information EBANGA™ including the U.S. Prescribing Information, please go to: www.EBANGA.com.
- Press Release / Business Wire 10.20.2021
- Presentation / National Organization for Rare Disorders (NORD) 07.02.2021
- Media / NIH – Intramural Research Program Blog 02.10.2021
Ridgeback would like to acknowledge and thank our collaborators on the EBANGA™ (ansuvimab-zykl, mAb114) development program: